Drug interactions
Bicalutamide + Ruxolitinib
Severity: Minor
Bicalutamide and Ruxolitinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ruxolitinib is a CYP3A4 substrate, and bicalutamide is a weak CYP3A4 inhibitor. A clinically meaningful rise in ruxolitinib levels is unlikely, but cytopenias are dose related.
What this interaction means in plain words
Bicalutamide and Ruxolitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bicalutamide belongs to Endocrine; Ruxolitinib belongs to Oncology.
Why it happens
Weak CYP3A4 inhibition by bicalutamide may slightly reduce ruxolitinib clearance.
What to do
Monitor blood counts per routine ruxolitinib practice; no dose adjustment is needed.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bicalutamide and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bicalutamide
- Bicalutamide + Lomitapide Major
- Aminolevulinic acid + Bicalutamide Moderate
- Bicalutamide + Eliglustat Moderate
- Bicalutamide + Flibanserin Moderate
- Bicalutamide + Ivosidenib Moderate
- Bicalutamide + Lonafarnib Moderate
Other interactions of Ruxolitinib
Frequently asked questions
Can I take Bicalutamide with Ruxolitinib?
MediHelp rates the interaction as minor. Bicalutamide and Ruxolitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Ruxolitinib is a CYP3A4 substrate, and bicalutamide is a weak CYP3A4 inhibitor. A clinically meaningful rise in ruxolitinib levels is unlikely, but cytopenias are dose related.
How serious is the interaction between Bicalutamide and Ruxolitinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts per routine ruxolitinib practice; no dose adjustment is needed.
What other medicines interact with Bicalutamide?
MediHelp also lists interactions of Bicalutamide with, for example, Lomitapide, Aminolevulinic acid, Eliglustat. The full list is on the Bicalutamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
